Clinical Trial Update: FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan [NA]

View source ↗

Summary

A clinical trial evaluating FDG uptake and lung blood flow in pulmonary arterial hypertension before and after treatment with ambrisentan has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

Sponsor: Robert Scott Harris, M.D. | Conditions: Pulmonary Arterial Hypertension | NA | Status: WITHDRAWN